Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962146 | 1.00 | ESR1 (0.54) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL18573342 | 0.90 | CYP3A4 (0.50) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL3632062 | 0.87 | ESR1 (0.48) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL4918290 | 0.85 | ESR1 (0.46) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL14101198 | 0.85 | ESR1 (0.46) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL11648324 | 0.84 | ESR1 (0.70) | ESR1ESR2CYP3A4TDP1LMNA | |
| SCHEMBL40441 | 0.84 | ESR1 (0.70) | ESR1ESR2CYP3A4TDP1LMNA | |
| SCHEMBL3301825 | 0.83 | ESR1 (0.56) | ESR1ESR2CYP3A4TDP1LMNA | |
| SCHEMBL3785328 | 0.83 | ESR1 (0.45) | ESR1ESR2CYP3A4TDP1DRD1 | |
| SCHEMBL3304592 | 0.83 | ESR1 (0.56) | ESR1ESR2CYP3A4TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281747-A1 | COBALT PHOSPHINE ALKYL COMPLEXES FOR THE ASYMMETRIC HYDROGENATION OF ALKENES | NATIONAL SCIENCE FOUNDATION | 2013-10-24 | — | — | US | disclosed |
| US-20130281747-A1 | COBALT PHOSPHINE ALKYL COMPLEXES FOR THE ASYMMETRIC HYDROGENATION OF ALKENES | NATIONAL SCIENCE FOUNDATION | 2013-10-24 | — | — | US | disclosed |
| WO-2006057904-A1 | STEREOSELECTIVE PREPARATION OF 4-ARYL PIPERIDINE AMIDES BY ASYMMETRIC HYDROGENATION OF A PROCHIRAL ENAMIDE AND INTERMEDIATES OF THIS PROCESS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281747-A1 | COBALT PHOSPHINE ALKYL COMPLEXES FOR THE ASYMMETRIC HYDROGENATION OF ALKENES | CPNE4, FTH1, HRH3 | ESR1 2269/4885ESR2 1822/4885CYP3A4 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.